Gregory B. Sephton Joins Haug Partners LLP

April 20, 2020

Meet Haug Partners LLP newest partner, Gregory B. Sephton.

With over 25 years of experience in high stakes litigation, Gregory has represented leaders in the pharma and biopharma trades where his background covers diversified technologies involving medical devices, chemicals, pharmaceuticals, and biologicals.

Gregory has won billion dollar pharmaceutical and biotechnology patent cases in federal district courts and before the Patent Trial and Appeal Board (PTAB). While handling patent cases for antivirals, hypnotics, anti-fungals, anti-bacterials, and anti-ulcer drugs, including oral, intravenous, and liposomal drug formulation technologies, Gregory developed a deep understanding of Hatch-Waxman litigation. Gregory is also highly experienced in intellectual property counseling, due diligence, and transactions.

Gregory led Forward Pharma to a $1.25 billion settlement in its worldwide patent dispute with Biogen over rights to its Tecfidera® (multiple sclerosis) treatment.

Prior to joining Haug Partners LLP, Gregory was a Partner at Pierce Bainbridge and previously Kramer Levin Naftalis & Frankel LLP. Before that he was a partner at Fitzpatrick, Cella, Harper & Scinto (now Venable).

Gregory attended Suffolk University Law School ( J.D.), Brandeis University ( Ph.D.), and the University of Toronto (B.Sc. Hons.).